Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
35 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
uniQure NV - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'uniQure NV - Product Pipeline Review - 2014', provides an overview of the uniQure NV's pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of uniQure NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of uniQure NV including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of uniQure NV's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the uniQure NV's pipeline products Reasons to buy - Evaluate uniQure NV's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of uniQure NV in its therapy areas of focus - Identify new drug targets and therapeutic classes in the uniQure NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of uniQure NV and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of uniQure NV - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of uniQure NV and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 4 List of Figures 4 uniQure NV Snapshot 5 uniQure NV Overview 5 Key Information 5 Key Facts 5 uniQure NV - Research and Development Overview 6 Key Therapeutic Areas 6 uniQure NV - Pipeline Review 8 Pipeline Products by Stage of Development 8 Pipeline Products - Monotherapy 9 uniQure NV - Pipeline Products Glance 10 uniQure NV - Late Stage Pipeline Products 10 Phase III Products/Combination Treatment Modalities 10 uniQure NV - Clinical Stage Pipeline Products 11 Phase I Products/Combination Treatment Modalities 11 uniQure NV - Early Stage Pipeline Products 12 Preclinical Products/Combination Treatment Modalities 12 uniQure NV - Drug Profiles 13 alipogene tiparvovec 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 AMT-060 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 AMT-110 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 AMT-021 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 AMT-090 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 Gene Therapy for Hemophilia A 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 Gene Therapy to Activate S100-A1 for Congestive Heart Failure 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 uniQure NV - Pipeline Analysis 22 uniQure NV - Pipeline Products by Target 22 uniQure NV - Pipeline Products by Route of Administration 23 uniQure NV - Pipeline Products by Molecule Type 24 uniQure NV - Pipeline Products by Mechanism of Action 25 uniQure NV - Recent Pipeline Updates 26 uniQure NV - Dormant Projects 31 uniQure NV - Discontinued Pipeline Products 32 Discontinued Pipeline Product Profiles 32 AMT-080 32 uniQure NV - Locations And Subsidiaries 33 Head Office 33 Other Locations & Subsidiaries 33 Appendix 34 Methodology 34 Coverage 34 Secondary Research 34 Primary Research 34 Expert Panel Validation 34 Contact Us 35 Disclaimer 35
List of Tables uniQure NV, Key Information 5 uniQure NV, Key Facts 5 uniQure NV - Pipeline by Indication, 2014 7 uniQure NV - Pipeline by Stage of Development, 2014 8 uniQure NV - Monotherapy Products in Pipeline, 2014 9 uniQure NV - Phase III, 2014 10 uniQure NV - Phase I, 2014 11 uniQure NV - Preclinical, 2014 12 uniQure NV - Pipeline by Target, 2014 22 uniQure NV - Pipeline by Route of Administration, 2014 23 uniQure NV - Pipeline by Molecule Type, 2014 24 uniQure NV - Pipeline Products by Mechanism of Action, 2014 25 uniQure NV - Recent Pipeline Updates, 2014 26 uniQure NV - Dormant Developmental Projects,2014 31 uniQure NV - Discontinued Pipeline Products, 2014 32 uniQure NV, Subsidiaries 33
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.